Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks

Conditions:   Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Influenza Type BIntervention:   Sponsor:   LG Life SciencesNot yet recruiting - verified October 2014

Source: ClinicalTrials.gov - October 5, 2014 Category: Research Source Type: clinical trials